Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myasthenia Gravis: early-phase trial registry
20 of 33 indexed Myasthenia Gravis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 20 currently recruiting · #463 of 28,707 conditions by registered trial count
Myasthenia Gravis: 33 US clinical trials tracked, 20 recruiting.
Myasthenia Gravis is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 6 of these trials.
Enrollment posture brief
Registry condition myasthenia-gravis
OPEN 20 | RECR 61% | LATE 5 | EARLY 11 | RANK #463 | SPON 6
Volume-matched condition peers
Nearest open-share peer: HIV Prevention (61% recruiting · 33 trials)
Myasthenia Gravis lists 20 open slots (61% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myasthenia Gravis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myasthenia Gravis is recruiting above its size-band peers.
20 of 33 indexed trials (60.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Myasthenia Gravis research.
argenx accounts for 6 of 33 trials (18.2%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Myasthenia Gravis enrolment sits around 96 participants.
Median target enrolment is 96 among the 33 trials that report a genuine target (sentinel values excluded). 17 of those (51.5%) plan for fewer than 100 participants.
-
Myasthenia Gravis splits between interventional and observational designs.
23 interventional and 10 observational studies make up this index (69.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
ZS Associates
NCT06866483
The EXPLORE MG Registry for Myasthenia Gravis
Yale University
NCT03792659
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
argenx
NCT06298565
Vitaccess Real MG Registry
Vitaccess
NCT06064461
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
argenx
NCT06299748
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
University of California, San Francisco
NCT06940323
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development
NCT04951622
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
Ad scientiam
NCT05564936
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06220201
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Janssen Research & Development
NCT07217587
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
ImmunAbs
NCT07250750
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NMD Pharma A/S
NCT06414954
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
argenx
NCT07294170
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
NCT07284420
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
NCT06193889
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
COUR Pharmaceutical Development Company
NCT06106672
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
University of Missouri-Columbia
NCT07478172
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx
NCT06626919
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
HealthPartners Institute
NCT06491238
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development
NCT05265273
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
Yale University
NCT06002945
Myasthenia Gravis Inebilizumab Trial
Amgen
NCT04524273
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
argenx
NCT06298552
SP Thoracic IDE Study
Intuitive Surgical
NCT05150210
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
ZS Associates
NCT06381284
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
University of Alabama at Birmingham
NCT00294658
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Beth Israel Deaconess Medical Center
NCT02118805
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Yale University
NCT02110706
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
NCT02965573
Acupuncture in Myasthenia Gravis (AcuMG)
HealthPartners Institute
NCT05230082
Clinical Trial to Improve the Magnetic Levator Prosthesis
Massachusetts Eye and Ear Infirmary
NCT03818204
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Immunovant Sciences
NCT03863080
Yogic Breathing Exercise for People With Amyotrophic Lateral Sclerosis
University of Alabama at Birmingham
NCT05979688
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 7 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Myasthenia Gravis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myasthenia Gravis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myasthenia Gravis page
33 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Myasthenia Gravis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most Myasthenia Gravis trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myasthenia Gravis condition card totals 33 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.